Value of serum and induced sputum surfactant protein-D in chronic obstructive pulmonary disease

Multidisciplinary Respiratory Medicine

Volumn 8, Issue 5, 2013, Pages

  Ozyurek, Berna Akinci ^a   Ulasli, Sevinc Sarinc ^b   Bozbas, Serife Savas ^c   Bayraktar, Nilufer ^c   Akcay, Sule ^c  

^a Ataturk Chest Disease and Thoracic Surgery Education and Research Hospital Ankara   (Turkey)

^b AFYON KOCATEPE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^c BASKENT UNIVERSITY   (Turkey)

Author keywords

Chronic obstructive pulmonary disease; Induced sputum; Surfactant protein D

Indexed keywords

SURFACTANT PROTEIN D;

ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CORTICOSTEROID THERAPY; FEMALE; FOLLOW UP; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; FUNCTIONAL RESIDUAL CAPACITY; HUMAN; HUMAN EXPERIMENT; LUNG FUNCTION TEST; MALE; PROTEIN BLOOD LEVEL; RESIDUAL VOLUME; SPUTUM ANALYSIS; TOTAL LUNG CAPACITY;

EID: 84879904337     PISSN: 1828695X     EISSN: 20496958     Source Type: Journal    
DOI: 10.1186/2049-6958-8-36     Document Type: Article

References (22)

1. Barnes PJ, Celi BR: Systemic manifestations and comorbidities of COPD. Eur Respir J 2009, 33:1165-1185.
2. Lomas DA, Silverman EK, Edwards LD, Locantore NW, Miller BE: Serum surfactant protein D is steroid sensitive and associated with exacerbations of COPD. Eur Respir J 2009, 34:95-102.
3. Sin DD, Leung R, Gan WQ, Man SP: Circulating surfactant protein D as a potential lung-specific biomarker of health outcomes in COPD: a pilot study. BMC Pulm Med 2007, 7: 13.
4. Crouch EC: Surfactant protein-D and pulmonary host defense. Respir Res 2000, 1:93-108.
5. Honda Y, Kuroki Y, Matsuura E, Nagae H, Takahashi H, Akino T, Abe S: Pulmonary surfactant protein D in sera and bronchoalveolar lavage fluids. Am J Respir Crit Care Med 1995, 152(6 Pt1):1860-1866.
6. Betsuyaku T, Kuroki Y, Nagai K, Nasuhara Y, Nishimura M: Effects of ageing and smoking on SP-A and SP-D levels in bronchoalveolar lavage fluid. Eur Respir J 2004, 24(6):964-970. (Pubitemid 39642287)
7. From the Global Strategy for the Diagnosis, Management and Prevention of COPD: Global Initiative for Chronic Obstructive Lung Disease (GOLD). 2011. http://www.goldcopd.org/.
8. Anthonisen NR, Manfreda J, Warren CP, Hershfield ES, Harding GK, Nelson NA: Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987, 106:196-204. (Pubitemid 17009877)
9. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, van der Grinten CP, Gustafsson P, Jensen R, Johnson DC, MacIntyre N, McKay R, Navajas D, Pedersen OF, Pellegrino R, Viegi G, Wanger J: ATS/ERS Task Force. Standardisation of spirometry. Eur Respir J 2005, 26(2):319-338. (Pubitemid 41079078)
10. Dar KA, Shahid M, Mubeen A, Bhargava R, Ahmad Z, Ahmad I, Islam N: The role of noninvasive methods in assessing airway inflammation and structural changes in asthma and COPD. Monaldi Arch Chest Dis 2012, 77(1):8-18.
11. Rytila PH, Lindqvist AE, Laitinen LA: Safety of sputum induction in chronic obstructive pulmonary disease. Eur Respir J 2000, 15:1116-1119. (Pubitemid 30399284)
12. Vlachos-Mayer H, Leigh R, Sharon RF, Hussack P, Hargreave FE: Success and safety of sputum induction in the clinical setting. Eur Respir J 2000, 16(5):997-1000. (Pubitemid 32049393)
13. Hacievliyagil SS, Gunen H, Mutlu LC, Karabulut AB, Temel I: Association between cytokines in induced sputum and severity of chronic obstructive pulmonary disease. Respir Med 2006, 100(5):846-854. Epub 2005 Oct 7.
14. Sørensen GL, Hjelmborg JB, Kyvik KO, Fenger M, Høj A, Bendixen C, Sørensen TI, Holmskov U: Genetic and environmental influences of surfactant protein D serum levels. Am J Physiol Lung Cell Mol Physiol 2006, 290(5):L1010-L1017. (Pubitemid 43725064)
15. Sims MW, Tal-Singer RM, Kierstein S, Musani AI, Beers MF, Panettieri RA, Haczku A: Chronic obstructive pulmonary disease and inhaled steroids alter surfactant protein D (SP-D) levels: a cross-sectional study. Respir Res 2008, 9:13. doi:10.1186/1465-9921-9-13.
16. Ishikawa N, Hattori N, Tanaka S, Horimasu Y, Haruta Y, Yokoyama A, Kohno N, Kinnula VL: Levels of surfactant proteins A and D and KL-6 are elevated in the induced sputum of chronic obstructive pulmonary disease patients: a sequential sputum analysis. Respiration 2011, 82(1):10-18.
17. Gunen H, Hacievliyagil SS, Yetkin O, Ibas G, Mutlu LC, Pehlivan E: Prevalence of COPD: first epidemiological study of a large region in Turkey. Eur J Intern Med 2008, 19:499-504.
18. Wedzicha JA, Donaldson GC: Exacerbations of chronic obstructive pulmonary disease. Respir Care 2003, 48:1204-1213.
19. Agusti AG, Noguera A, Sauleda J, Sala E, Pons J, Busquets X: Systemic effects of chronic obstructive pulmonary disease. Eur Respir J 2003, 21:347-360. (Pubitemid 36204553)
20. Wouters EF, Groenewegen KH, Dentener MA, Vernooy JH: Systemic inflammation in chronic obstructive pulmonary disease: the role of exacerbations. Proc Am Thorac Soc 2007, 4:626-634. (Pubitemid 350291625)
21. Sin DD, Pahlavan PS, Man SF: Man surfactant protein D:A lung specific biomarker in COPD? Ther Adv Respir Dis 2008, 2:65-74. (Pubitemid 351472132)
22. Shakoori TA, Sin DD, Ghafoor F, Bashir S, Bokhari SN: Serum surfactant protein D during acute exacerbations of chronic obstructive pulmonary disease. Dis Markers 2009, 27:287-294.